Virax Biolabs Adds Three ImmuneSelect Distributors in Mainland China
Virax Biolabs, through its Shanghai Xitu Consulting subsidiary, entered three non-exclusive distribution agreements with AmyJet Scientific, Jiangsu Real-Gen Biotechnology, and Zhixi (Shanghai) Biotechnology for ImmuneSelect research-use immune profiling products. The distributors will purchase products for resale and manage local sales, customer engagement and product-use training, while Virax provides product supply, documentation and technical support. The agreements cover specified customer segments across Be...
Key takeaways
The three distribution agreements are non-exclusive and were entered into through Virax's China subsidiary, Shanghai Xitu Consulting.
Distributors will purchase ImmuneSelect products from Virax for resale and will manage local sales, customer engagement and customer training.
AmyJet will target industrial and biotechnology customers in Beijing, Shanghai and Hubei.
Jiangsu Real-Gen will target academic, biopharmaceutical and other research customers in Jiangsu, Anhui and Shandong.
Zhixi adds a Shanghai academic sales channel and is under common ownership with Shanghai KEL Biotechnology.
The initial product focus is ELISpot assay plates and antigen-specific peptide pools for infectious-disease, vaccine and cellular-immunity research.
The appointments build on initial ImmuneSelect sales in mainland China and complement Virax's previously announced Fosun Diagnostics supply agreement covering six Southeast Asian markets.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow VRAX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.